SAHA is an FDA-approved chemotherapeutic agent that has found success as a treatment for T- cell lymphoma. This histone deacetylase (HDAC) inhibitor is additionally part of over 240 past or ongoing clinical trials ( that seek to examine SAHA efficacy as a treatment option for many other cancer subtypes and pathologies. Despite widespread study at the clinical level, the therapeutic potential of SAHA and other HDAC inhibitors is hampered by our rudimentary understanding of the molecular mechanisms that mediate their actions. Our proposed studies will shed light upon such mechanisms and characterize the response of the SIN3 HDAC complexes to SAHA. Our objective is to characterize the functional dynamics of SIN3A and SIN3B complexes. We hypothesize that SIN3A and SIN3B complexes possess divergent functional attributes and are differentially responsive to HDAC inhibitors. Our objective will be addressed through two aims.
In aim 1, we will characterize the biophysical properties of SIN3A and SIN3B complexes. To examine the SIN3A and SIN3B core complex architectural arrangements and responses to HDAC inhibitors, we will employ crosslinking mass spectrometry to identify sites of protein-protein interactions within the complex and monitor their responses to HDAC inhibitors.
In aim 2, we will examine the unique roles held by SIN3A and SIN3B proteins within SH-SY5Y neuroblastoma and HEK293 cells and characterize their influences on biological pathways. In the process of addressing these central biological issues, we will make significant contributions to the field of quantitative proteomics by developing an assay system capable of quantifying the dynamics of protein-protein interactions via crosslinking mass spectrometry. As SAHA and other HDAC inhibitors are already components of clinical treatment plans, the proposed studies will produce information that will be immediately useful as we define the therapeutic potential of SAHA. Long- term, these findings will provide the groundwork for the development of HDAC inhibitors that target specific aspects of HDAC complexes and produce few off-target effects.

Public Health Relevance

SIN3 HDAC complexes are targets of suberoylanilide hydroxamic acid (SAHA) and other FDA- approved chemotherapeutic HDAC inhibitors. Despite the growing inclusion of HDAC inhibitors in clinical trials, our knowledge of SIN3 functional properties remains lacking. The proposed research plan will delineate the actions of SIN3A and SIN3B complexes within the cell and assess the biophysical and functional responses of these complexes to SAHA application.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Postdoctoral Individual National Research Service Award (F32)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Flicker, Paula F
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stowers Institute for Medical Research
Kansas City
United States
Zip Code
Banks, Charles A S; Miah, Sayem; Adams, Mark K et al. (2018) Differential HDAC1/2 network analysis reveals a role for prefoldin/CCT in HDAC1/2 complex assembly. Sci Rep 8:13712
Banks, Charles A S; Thornton, Janet L; Eubanks, Cassandra G et al. (2018) A Structured Workflow for Mapping Human Sin3 Histone Deacetylase Complex Interactions Using Halo-MudPIT Affinity-Purification Mass Spectrometry. Mol Cell Proteomics 17:1432-1447